Trial ID or NCT#

NCT02306161

Status

RECRUITING

Purpose

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Official Title

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Eligibility Criteria

Ages Eligible for Study: Younger than 50 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Sheri L. Spunt, MD, MBA
Pediatric oncologist, Sarcoma specialist
Endowed Professor of Pediatric Cancer
Neyssa Marina

Contact us to find out if this trial is right for you.

CONTACT

Christina Baggott
(650) 497-7659